A closer look at the baseline-observation-carriedforward (BOCF)

Patient Preference and Adherence

Volumn 4, Issue , 2010, Pages 11-16

  Liu Seifert, Hong ^a   Zhang, Shuyu ^a   D'Souza, Deborah ^a   Skljarevski, Vladimir ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Discontinuation; Pain; Statistical; Treatment related

Indexed keywords

EID: 77952103170     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Liu G, Gould AL. Comparison of alternative strategies for analysis of longitudinal trials with dropouts. J Biopharm Stat. 2002;12(2): 207-226.
2. Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat. 2008;7(2): 93-106.
3. Mallinckrodt CH, Sanger TM, Dubé S, et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry. 2003;53(8):754-760.
4. Mallinckrodt CH, Lane PW, Schnell D, Peng Y, Mancuso JP. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Inf J. 2008;42(4):303-319.
5. Shao J, Jordan DC, Pritchett YL. Baseline observation carry forward: reasoning, properties, and practical issues. J Biopharm Stat. 2009;19(4):672-684.
6. Skljarevski V, Desaiah D, Liu-Seifert H, et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine. 2009. In press.
7. Chappell AS, Desaiah D, Liu-Seifert H, et al. Duloxetine 60 to 120 mg once daily versus placebo in the treatment of patients with osteoarthritis knee pain. [Poster] Presented at the American Academy of Pain Medicine (AAPM) - 25th Annual Meeting, Honolulu, HI, USA; Jan 28-31, 2009.
8. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105-121.
9. Andersen JW, Van Der Horst C, Gorski H, Fass RJ. Conference on Retroviruses and Opportunistic Infections. The association of site with early study discontinuation on HIV clinical studies in the protease inhibitor era: DACS200. Program Abstr 8th Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 8th 2001 Chic Ill; 2001 Feb 4-8;8:188 (abstract no. 486).
10. Anderson JW, Fass R, van der Horst C. Factors associated with early study discontinuation in AACTG studies, DACS 200. Contemp Clin Trials. 2007;28(5):583-592.